Why Moderna Stock Could Still Be More Than 50% Overvalued
Moderna (NASDAQ: MRNA) took the world by storm in 2020. The company quickly became a leader in the race to develop COVID-19 vaccines. Since the middle of last year, though, Moderna has been through storms of its own.